Clinical-stage biotech Alzheon has completed a $100 million Series E financing round to advance the development and commercialization of its oral drug for Alzheimer’s disease. The drug, called ALZ-801 (valiltramiprosate), is designed to inhibit the formation of soluble toxic beta amyloid oligomers, which are implicated in the cognitive decline observed in Alzheimer’s patients. The small molecule acts upstream of other late-stage amyloid-targeting treatments, offering a potentially more effective intervention by addressing the early formation of neurotoxic aggregates.
The new funding will be used to complete the current APOLLOE4 Phase 3 study to evaluate the efficacy and safety of ALZ-801 in patients with early Alzheimer’s disease. It will also support Alzheon’s plans to submit a New Drug Application (NDA) in 2024 based on the study’s outcomes, as well as preparing the manufacturing processes and commercial launch of ALZ-801, which is potentially the first oral disease-modifying therapy for Alzheimer’s.
“This latest fundraising ensures that we will have sufficient capital to complete our pivotal Phase 3 program and prepare commercialization of oral ALZ-801/valiltramiprosate with runway well into 2026,” said Ken Mace, CFO of Alzheon. “ALZ-801 has the potential to disrupt the Alzheimer’s treatment paradigm by slowing the progression of this relentless and debilitating disease, and the results from our pivotal APOLLOE4 Phase 3 trial will set the stage for the potential NDA filing this year, followed by the U.S. commercial launch in 2025.”
The pivotal APOLLOE4 Phase 3 study particularly targets patients with two copies of the APOE4/4 gene, a high-risk group that constitutes approximately 15% of Alzheimer’s patients, including actor Chris Hemsworth. The study, which has screened over 6,000 patients and enrolled 325 subjects, will conclude in the third quarter of 2024. Positive results could pave the way for regulatory approval and subsequent commercialization.
“We are at the dawn of a new era in the treatment of Alzheimer’s disease, and our novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients,” said Dr Martin Tolar, CEO of Alzheon. “Our well-differentiated drug candidate with a favorable safety profile, showing no increased risk of vasogenic brain edema in more than 3,000 AD patients, is positioned to potentially become the first oral disease modifying therapy for the treatment of Alzheimer’s disease.”
In addition to the Phase 3 study, ALZ-801 has been evaluated in a two-year Phase 2 biomarker trial involving 84 patients, including 31 APOE4/4 homozygotes. This trial, completed in late 2023, is currently in a fourth-year extension phase. The study’s primary goal is to assess the effects of ALZ-801 on biomarkers of Alzheimer’s pathology, alongside its clinical efficacy, safety, tolerability, and pharmacokinetic profile over 208 weeks of treatment.
Alzheon envisions extending the use of ALZ-801 beyond APOE4/4 homozygotes to include patients with one copy of the APOE4 gene and even noncarriers. The company says it is also focusing on a future precision medicine approach, leveraging individual genetic and biomarker information to tailor therapies that offer the greatest benefit to specific patient subsets.
The funding round, which was led by Alerce Medical Technology Partners, follows a $50 million Series D round completed in 2022.
“At Alerce, we focus on investing in companies in the late stages of development that are developing lifesaving drugs or devices with the potential to benefit millions of patient lives,” said Muneer Satter, Managing Partner of Alerce. “Alzheon’s ALZ-801 provides an innovative precision-medicine solution in an emerging Alzheimer’s pipeline with a path to potential approval in 2025.”
News
Scientists discover natural ‘brake’ that could stop harmful inflammation
Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation—a breakthrough that could lead to new treatments for chronic diseases affecting millions worldwide. Inflammation is the [...]
A Forgotten Molecule Could Revive Failing Antifungal Drugs and Save Millions of Lives
Scientists have uncovered a way to make existing antifungal drugs work again against deadly, drug-resistant fungi. Fungal infections claim millions of lives worldwide each year, and current medical treatments are failing to keep pace. [...]
Scientists Trap Thyme’s Healing Power in Tiny Capsules
A new micro-encapsulation breakthrough could turn thyme’s powerful health benefits into safer, smarter nanodoses. Thyme extract is often praised for its wide range of health benefits, giving it a reputation as a natural medicinal [...]
Scientists Develop Spray-On Powder That Instantly Seals Life-Threatening Wounds
KAIST scientists have created a fast-acting, stable powder hemostat that stops bleeding in one second and could significantly improve survival in combat and emergency medicine. Severe blood loss remains the primary cause of death from [...]
Oceans Are Struggling To Absorb Carbon As Microplastics Flood Their Waters
New research points to an unexpected way plastic pollution may be influencing Earth’s climate system. A recent study suggests that microscopic plastic pollution is reducing the ocean’s capacity to take in carbon dioxide, a [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from Frank Boehm
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
New Book! NanoMedical Brain/Cloud Interface – Explorations and Implications
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
Miller School Researchers Pioneer Nanovanilloid-Based Brain Cooling for Traumatic Injury
A multidisciplinary team at the University of Miami Miller School of Medicine has developed a breakthrough nanodrug platform that may prove beneficial for rapid, targeted therapeutic hypothermia after traumatic brain injury (TBI). Their work, published in ACS [...]
COVID-19 still claims more than 100,000 US lives each year
Centers for Disease Control and Prevention researchers report national estimates of 43.6 million COVID-19-associated illnesses and 101,300 deaths in the US during October 2022 to September 2023, plus 33.0 million illnesses and 100,800 deaths [...]
Nanomedicine in 2026: Experts Predict the Year Ahead
Progress in nanomedicine is almost as fast as the science is small. Over the last year, we've seen an abundance of headlines covering medical R&D at the nanoscale: polymer-coated nanoparticles targeting ovarian cancer, Albumin recruiting nanoparticles for [...]
Lipid nanoparticles could unlock access for millions of autoimmune patients
Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted lipid nanoparticles (tLNPs) is designed to deliver [...]
The Brain’s Strange Way of Computing Could Explain Consciousness
Consciousness may emerge not from code, but from the way living brains physically compute. Discussions about consciousness often stall between two deeply rooted viewpoints. One is computational functionalism, which holds that cognition can be [...]
First breathing ‘lung-on-chip’ developed using genetically identical cells
Researchers at the Francis Crick Institute and AlveoliX have developed the first human lung-on-chip model using stem cells taken from only one person. These chips simulate breathing motions and lung disease in an individual, [...]
Cell Membranes May Act Like Tiny Power Generators
Living cells may generate electricity through the natural motion of their membranes. These fast electrical signals could play a role in how cells communicate and sense their surroundings. Scientists have proposed a new theoretical [...]
This Viral RNA Structure Could Lead to a Universal Antiviral Drug
Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for enteroviruses. A new study from the University of Maryland, Baltimore County (UMBC), published in Nature Communications, explains how enteroviruses begin reproducing [...]
